Background—The success of percutaneous intervention in peripheral arterial disease is
limited by restenosis. The aim of the present pilot study was to evaluate a novel method of …

Background The treatment of peripheral artery disease with percutaneous transluminal
angioplasty is limited by the occurrence of vessel recoil and restenosis. Drug-coated …

Objectives: This study sought to evaluate the safety and efficacy of the Lutonix drug-coated
balloon (DCB) coated with 2 μg/mm2 paclitaxel and a polysorbate/sorbitol carrier for …

Objectives: The purpose of this study was to evaluate the 5-year follow-up (FU) data of the
THUNDER (Local Taxan With Short Time Contact for Reduction of Restenosis in Distal …

Background Drug-eluting stents reduce restenosis in coronary arteries, but clinical trials
have failed to prove their efficacy in peripheral arteries. We investigated the use of paclitaxel …

Background—Peripheral percutaneous transluminal angioplasty is fraught with a substantial
risk of restenosis and reintervention. A drug-eluting balloon (DEB) based on a novel coating …

Purpose: To provide a qualitative analysis and quantitative synthesis of randomized
controlled trials (RCTs) investigating paclitaxel-coated balloons (PCBs) in the …

Objectives: The aim of this study was to investigate the efficacy and safety of a new
paclitaxel-coated balloon catheter in the treatment of stenotic or occluded femoropopliteal …

Objectives: This study evaluated the use of a paclitaxel-eluting balloon (PEB) for treatment of
femoropopliteal arterial disease. Background: Conventional balloon angioplasty and …

Background—In disease of the femoropopliteal artery, paclitaxel-coated balloon (PCB)
therapy improved angiographic outcomes as compared with uncoated balloon (UCB) …